PCN86 Cost-Utility Analysis of Nilotinib Compared to Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.1203
https://www.valueinhealthjournal.com/article/S1098-3015(12)01268-5/fulltext
Title :
PCN86 Cost-Utility Analysis of Nilotinib Compared to Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)01268-5&doi=10.1016/j.jval.2012.03.1203
First page :
A223
Section Title :
Cancer
Open access? :
No
Section Order :
728